Company History

Founded in 1996 in Sweden as Cortendo AB, our original focus was on regulating cortisol secretion in patients with diabetes.

In the course of reinventing, refocusing, and reinvigorating the company, Strongbridge Biopharma has reached a series of pivotal business and clinical milestones.

Strategic Acquisitions

In January 2018, Strongbridge Biopharma acquired the U.S. and Canadian rights to MACRILENTM (macimorelin). In December 2016, Strongbridge Biopharma acquired the U.S. rights to KEVEYIS® (dichlorphenamide). These acquisitions are part of our commitment to expand our portfolio and help meet the needs of patients with rare diseases that are underdiagnosed and undertreated.

Key Milestones

Recent business and clinical milestones reflect our focus on rare diseases and our organizational agility in meeting the challenges of drug development and commercialization.
Jan 2018

Acquired MACRILEN (macimorelin) from Aeterna Zentaris for the diagnosis of Adult Growth Hormone Deficiency

Jul 2017

Last patient enrolled (LPI) in phase 3 SONICS trial of RECORLEV (levoketoconazole) for endogenous Cushing's syndrome

Apr 2017

Launched KEVEYIS (dichlorphenamide) for Primary Periodic Paralysis

Dec 2016

Acquired KEVEYIS (dichlorphenamide) from Taro Pharmaceutical Industries for Primary Periodic Paralysis

Jun 2015

Acquired veldoreotide, being studied for acromegaly, from Aspireo Pharmaceuticals

Aug 2014

First patient enrolled in phase 3 SONICS trial of RECORLEV in endogenous Cushing's syndrome

Aug 2012

RECORLEV received EU orphan drug designation

Mar 2012

RECORLEV received US orphan drug designation

Feb 2012

Pivoted RECORLEV focus from diabetes to Cushing's syndrome

Please see KEVEYIS Important Safety Information and Full Prescribing Information. Please see MACRILEN Important Safety Information and Full Prescribing Information.

The safety and efficacy of RECORLEV™ (levoketoconazole) and veldoreotide have not been established.
Learn more about our investigational therapies

RECORLEV (levoketoconazole) and veldoreotide

© 2018 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA® is a registered trademark of the Strongbridge Biopharma plc. companies, which include Strongbridge Ireland Limited and Strongbridge U.S. Inc.
KEVEYIS® is a registered trademark licensed exclusively in the U.S. to Strongbridge Biopharma plc.
MACRILEN is a trademark of Aeterna Zentaris GmbH, licensed exclusively in the U.S. and Canada to Strongbridge Ireland Limited.
MLR-0010 V13 01/2018

900 Northbrook Drive, Suite 200
Trevose, PA 19053
United States
Phone: +1 610-254-9200
info@strongbridgebio.com

Privacy Statement
Compliance Program